Substance / Medication

Saquinavir mesylate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Bioequivalence study of two oral tablet formulations containing saquinavir mesylate boosted with ritonavir in healthy male subjects.
Yerino Gustavo A, Halabe Emilia K, Zini Elvira et al. · Arzneimittelforschung · 2011
PMID: 21950153RCT
Intranasal in situ gel loaded with saquinavir mesylate nanosized microemulsion: preparation, characterization, and in vivo evaluation.
Hosny Khaled Mohamed, Hassan Ali Habiballah · Int J Pharm · 2014
PMID: 25178831Observational
Development and physicochemical characterization of saquinavir mesylate solid dispersions using Gelucire 44/14 or PEG 4000 as carrier.
Caon Thiago, Konig Ricardo Augusto, da Cruz Ariadne Cristiane Cabral et al. · Arch Pharm Res · 2013
PMID: 23700292Observational
Hydrogel containing mPEG-PLGA nanoparticles for the vaginal delivery of saquinavir mesylate against HIV infection.
Tiboni Mattia, Cespi Marco, Casettari Luca et al. · Eur J Pharm Sci · 2023
PMID: 37774955Other
A New Saquinavir Mesylate-Sodium Decyl Sulfate Salt Discovered by Serendipity during an Anomalous Dissolution Test.
Fandaruff Cinira, Caon Thiago, Araya-Sibaja Andrea Mariela et al. · Pharm Res · 2022
PMID: 35064418Other
Pharmacokinetics of Saquinavir Mesylate from Oral Self-Emulsifying Lipid-Based Delivery Systems.
Caon Thiago, Kratz Jadel Muller, Kuminek Gislaine et al. · Eur J Drug Metab Pharmacokinet · 2017
PMID: 26846485Preclinical
Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting.
Mahajan Hitendra S, Mahajan Milind S, Nerkar Pankaj P et al. · Drug Deliv · 2014
PMID: 24128122Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Saquinavir mesilate (substance)
SNOMED CT
108701009
UMLS CUI
C0286737

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.